1. TGA - Adults
2. TGA - Paediatrics
3. CE Mark - Adults
4. CE Mark - Paediatrics
Also CE mark enables facilitation into some Asian countries.
Some of these approvals are now circa 4 months old so management getting this out asap isn't a rush imo.
The timing couldn't be better for RAP shareholders. It's highlighting the need for a digital respiratory diagnostic & management tool. This will create opportunities that should be visible to us shareholders shortly imo.
All the recent talk is on CV and respiratory illness and yet we still have Sleep Apnea up our sleeve.
Good news coming imo.
RAP Price at posting:
19.0¢ Sentiment: Buy Disclosure: Held